Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

343862

Sigma-Aldrich

1-Bromoheptadecafluorooctane

99%

Sinonimo/i:

Heptadecafluorooctyl bromide, Perfluorooctyl bromide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula condensata:
CF3(CF2)7Br
Numero CAS:
Peso molecolare:
498.96
Beilstein:
2016022
Numero CE:
Numero MDL:
Codice UNSPSC:
12352100
ID PubChem:
NACRES:
NA.22

Saggio

99%

Forma fisica

liquid

Indice di rifrazione

n20/D 1.305 (lit.)

P. eboll.

142 °C (lit.)

Densità

1.93 g/mL at 25 °C (lit.)

Stringa SMILE

FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br

InChI

1S/C8BrF17/c9-7(22,23)5(18,19)3(14,15)1(10,11)2(12,13)4(16,17)6(20,21)8(24,25)26
WTWWXOGTJWMJHI-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

1-Bromoheptadecafluorooctane (perfluorooctyl bromide) is a perfluorocarbon. Poly(ethylene glycol)ylated polyester nanocapsules of perfluorooctyl bromide were surface-decorated with a RGD (arginine-glycine-aspartic acid) peptide, were used for tumor imaging. Nanocapsules of perfluorooctyl bromide have been developed as dual contrast agent for ultrasonography and Magnetic Resonance Imaging (MRI).

Applicazioni

1-Bromoheptadecafluorooctane (perfluorooctyl bromide) can be used as contrast agent in the vascular system for fluorine-19 magnetic resonance imaging or as synthetic oxygen carrier. It was also employed as oxygen carrier in the emulsions used as blood substitutes.

Pittogrammi

Exclamation mark

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type ABEK (EN14387) respirator filter


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 3

1 of 3

Céline Giraudeau et al.
Angiogenesis, 16(1), 171-179 (2012-10-12)
Molecular imaging with magnetic resonance imaging (MRI) targeted contrast agents has emerged as a promising diagnostic approach in cancer research to detect associated biomarkers. In this work, the potential of (19)F MRI was investigated to detect angiogenesis with α(ν)β(3)-targeted perfluorooctylbromide
G Srinivas Rao et al.
Journal of environmental science & engineering, 52(2), 137-146 (2010-12-01)
A systematic study has been carried out to explore the physico-chemical characteristics of groundwater in Greater Visakhapatnam Municipal Corporation (GVMC) area. Water samples from 32 bore wells, 16 open wells and two reservoirs at various locations in GVMC area were
Mitsuhiro Isaka et al.
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 14(6), 363-368 (2009-01-10)
Perfluoro-octyl bromide (PFOB), one of the perfluorochemical oxygen transporters, improved postischemic cardiac dysfunctions. Also norepinephrine (NE) is one of the important inducible factors on reperfusion arrhythmias (ventricular fibrillation [VF]). We used these methods to evaluate the relationship between PFOB emulsion
Ao Li et al.
Acta radiologica (Stockholm, Sweden : 1987), 54(3), 278-283 (2013-01-16)
Multimodal contrast agents usually containing two or more signal components can be used for several imaging modalities. Thus, complimentary information can be obtained by using just one kind of contrast agents. To investigate the potential of superparamagnetic perfluorooctylbromide nanoparticles (M-PFOBNP)
S A Snyder et al.
Veterinary and comparative oncology, 6(4), 213-223 (2009-01-31)
Human oncology has clearly demonstrated the existence of hypoxic tumours and the problematic nature of those tumours. Hypoxia is a significant problem in the treatment of all types of solid tumours and a common reason for treatment failure. Hypoxia is

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.